Treatment of Pellucid Marginal Degeneration

Abstract

Purpose: To summarize the recent trends in the treatment of pellucid marginal degeneration (PMD) based on available published data.Method and literature search: A PubMed search was conducted with combinations not limited to the following search terms: Pellucid marginal degeneration, Corneal ectasia, Corneal collagen cross-linking (CXL), Intracorneal ring segments (ICRS), Contact lens, Keratoplasty in corneal ectasia. A review of the search results was performed and relevant articles to the topic were included. Summary:Ophthalmologists have got a wide array of therapeutic modalities for the management of PMD. However, the key to optimal treatment is careful clinical assessment of patients and their visual requirements and tailoring the treatment to individual patients.

Coincident Pellucid Marginal Degeneration and Fuchs’ Endothelial Dystrophy

“…1 PMD has a 3:1 male predominance and typically presents between the ages of 20-50 years with declining vision, irregular astigmatism, and inferior steepening and thinning noted on corneal tomography. [2][3][4] Fuchs' endothelial corneal dystrophy (FECD) is the most common corneal dystrophy and the most common dystrophy-related indication for corneal transplantation. 5 FECD is characterized by progressive loss of corneal endothelial cells, a formation of guttae and decreased vision typically associated with corneal edema.…”

Pellucid Marginal Corneal Degeneration and Keratoconus: Differential Diagnosis and Management of Patients

“…Все вышеперечисленные методы хирургического лечения ПМД не идеальны. При наличии четких признаков прогрессирования ПМД оптимальным вариантом лечения является кросслинкинг роговицы [3,[12][13][14], в том числе в сочетании с имплантацией интрастромальных роговичных сегментов.…”